Skip to main content Back to Top

Beyond the Interaction Checker: A Deep Dive on Non-Traditional Drug Interactions with Immune Checkpoint Inhibitors

Broadcast Date: April 5, 2023


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Does risk level “C” always mean “continue”? Join us as we delve into the current state of immune checkpoint inhibitor drug interaction reporting in common drug information resources and discuss how these interactions may be interpreted in daily clinical practice.


Tonya SmithTonya Smith, PharmD, BCPS is Clinical Pharmacy Specialist in Palliative Care at Emory Healthcare in Atlanta, Georgia. Dr. Smith received her PharmD degree from the Medical University of South Carolina in Charleston, South Carolina. She completed her PGY1 Pharmacy Practice Residency and PGY2 Internal Medicine Pharmacy Residency at University of Utah Health in Salt Lake City, Utah. Prior to Emory, Dr. Smith practiced on the inpatient medical oncology service and the Supportive Oncology & Survivorship Clinic at the Huntsman Cancer Institute in Salt Lake City, Utah.

Jordan McPhersonJordan McPherson, PharmD, MS, BCOP is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at the Huntsman Cancer Institute, an NCI designated cancer hospital, at the University of Utah Health and Adjunct Assistant Professor at the University of Utah College of Pharmacy in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and is Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are well published in peer reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.

Relevant Financial Relationship Disclosures

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. 

More in this Series

On-Demand Webinar: Get to the Checkpoint: A Practical Perspective on Updates in Immunotherapy and Immune-Related Adverse Event Management

On-Demand Webinar: Ask the Experts: Check(point) Your Assumptions with Immunotherapy and Immune-Related Adverse Event Management

Engaging the Experts Podcast: This Interaction is a “Pain”: Cancer Pain Management Optimization During Treatment with Immune Checkpoint Inhibitors

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
This podcast is provided by ASHP and supported by educational grants from Bristol Myers Squibb and Merck.